Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 17:3:e28269.
doi: 10.4161/onci.28269. eCollection 2014.

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma

Dario Sangiolo  1 , Giulia Mesiano  2 , Loretta Gammaitoni  3 , Massimo Aglietta  4 , Giovanni Grignani  5
Affiliations

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma

Dario Sangiolo et al. Oncoimmunology. .

Abstract

Cytokine-induced killer (CIK) cells are T lymphocytes expanded ex vivo that are endowed with MHC-independent tumoricidal activity. We have recently demonstrated, in a preclinical setting, that CIK cells are active against autologous bone and soft tissue sarcomas. In particular, CIK cells killed a putative sarcoma stem cell population that may underlie disease relapse and chemoresistance.

Keywords: CIK cells; adoptive immunotherapy; cancer stem cells; sarcomas; solid tumors.

PubMed Disclaimer

Figures

None
Figure 1. Preclinical model unveiling the activity of cytokine-induced cells against autologous bone sarcoma and soft tissue sarcoma. Primary sarcoma cultures were generated from fresh surgical biopsies. Putative cancer stem cells (CSCs) were visualized upon the transduction of malignant cells with a lentiviral CSC-detecting vector encoding the enhanced variant of green fluorescent protein (eGFP) under the control of the OCT4 promoter (pRRL.sin.PPT.hOct4.eGFP.Wpre). Patient-derived cytokine-induced killer (CIK) cells were active in vitro and in vivo against autologous bone sarcoma (BS) and soft tissue sarcoma (STS) cells, including putative CSCs.
See this image and copyright information in PMC

References

    1. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS) J Clin Oncol. 2005;23:559–68. doi: 10.1200/JCO.2005.04.063. - DOI - PubMed
    1. Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET Consensus Panel of experts Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v198–203. doi: 10.1093/annonc/mdq209. - DOI - PubMed
    1. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71:634–9. doi: 10.1158/0008-5472.CAN-10-3220. - DOI - PubMed
    1. Wirths S, Malenke E, Kluba T, Rieger S, Müller MR, Schleicher S, Hann von Weyhern C, Nagl F, Fend F, Vogel W, et al. Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas. Stem Cells Transl Med. 2013;2:53–60. doi: 10.5966/sctm.2012-0055. - DOI - PMC - PubMed
    1. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31:4898–911. doi: 10.1038/onc.2011.656. - DOI - PMC - PubMed